ZEV Biotech
case study
Molecular diagnostics for emerging markets
Pre-Seed
Buenos Aires, Argentina

What's the Problem?

Today there is a limited access to molecular diagnostics in developing countries. This limitation occurs because of high equipment investment and high costs of consumables. Also, a lack of local technical assistance for recognized brands doing molecular diagnostics limits the possibilities. Leader companies need a high number of samples per platform use and have specific facilities requirements which make more difficult its implementation.

ZEV Biotech
ZEV Biotech
ZEV Biotech
ZEV Biotech

How are they Solving it?

ZEV Biotech has developed a complete Genomic Platform for molecular diagnosis adapted to developing countries market needs: -Modular equipment and low investment, allowing easy and cost-effective implementation -Low consumables costs -Scalable: Low number of samples per platform use -Versatile. Different pathologies can be diagnosed in the same platform use -Internal Quality Controls -Adaptable to every laboratory workflow -Internationaly validated.

AlgaeBio+

Next Startup

AlgaeBio+